Accutar Biotechnology
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8 Clarke Dr Ste 4, Cranbury, New Jersey,...Phone Number
(646) 462-5083Website
www.accutarbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Accutar Biotechnology
Accutar Biotech is a U.S.-based company that leverages artificial intelligence (AI) technology to enhance drug discovery processes. They employ a hybrid approach that combines computational drug design with wet lab validation to minimize the time and costs associated with traditional drug development. Their innovative AI solutions include tools like ChemiRise, Orbital, and Intelligent-SAR, aimed at accelerating drug discovery efforts. The company targets clients in the pharmaceutical and biotechnology sectors, focusing on transformative treatments for patients.Explore more
Accutar Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Accutar Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Accutar Biotechnology is spiking on competitors!
Accutar Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Accutar Biotechnology has new funding data
Click to see if Accutar Biotechnology had a recent Job posting/layoffs
Earning: See what the market has to say on Accutar Biotechnology recently announced quarterly report
Check if Accutar Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Accutar Biotechnology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Accutar Biotechnology
Recommended Actions
Find VP level buyers at Accutar Biotechnology
Find 3 more new buyers
Compare Similar Companies to Accutar Biotechnology
Compare insights from companies similar to Accutar Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Accutar Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Accutar Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Accutar Biotechnology.
Accutar Biotechnology financials insights
Gather financial insights about Accutar Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Accutar Biotechnology Tech Stack
A closer look at the technologies used by Accutar Biotechnology
See more technologies
Accutar Biotechnology News & Media
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer. The data will be presented in a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1, 2024. AC699 is a potent and selective orEvommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune will leverage Accutar's AI-empowered drug discovery platform for therapies targeting chronic inflammatory diseases PALO ALTO, Calif. and CRANBURY, N.J., Nov. 28, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat...Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage. "The initiation of this study distinguishes Accutar as the first company to successfully bring oAccutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer
CRANBURY, N.J. & SHANGHAI--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity. “The initiation of this study marks the second program from our chimeric degrader portfolio to enter the
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Accutar Biotechnology
Sign Up For FreeTo access detailed company insights
Accutar Biotech is a U.S.-based company that leverages artificial intelligence (AI) technology to enhance drug discovery processes. They employ a hybrid approach that combines computational drug design with wet lab validation to minimize the time and costs associated with traditional drug development. Their innovative AI solutions include tools lik... Read More
